X
    X
    X
    X

    Edwards Wildman's Ralph Loren Comments on Application for Drug Patent in India in World Intellectual Property Review

    News
    Ralph Loren, a Boston-based partner in Edwards Wildman's intellectual property practice, discussed how Roche has declined to pursue a patent application for a breast cancer drug in the Indian market in World Intellectual Property Review. In the article, "Roche Relinquishes Patent on Breast Cancer Drug in India," Loren said, "This was not an application for the underlying drug, it was a secondary patent that was adding to the original. If it were for a patent that underlies the finer details of a drug, that’s worth fighting but purely an add on would not." Loren added, "They [Roche] would have looked at this and thought, how much is it worth fighting? India is not a good environment for pharmaceuticals at the moment and at some point, there will be a cheaper version on the market. Roche would have thought they did not want to spend a huge amount of money on something they would be likely to lose."

    Explore Additional Topics

    Disclaimer

    Please understand that your communications with Locke Lord LLP through this website do not constitute or create an attorney-client relationship with Locke Lord LLP. Any information you send to Locke Lord LLP through this website is on a non-confidential and non-privileged basis. Therefore, do not send or include any information in your email that you consider to be confidential or privileged.